Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B, C, and Delta—Updates in Screening and Infection Prevention Opportunities for Eradication

  • New Technologies and Advances in Infection Prevention (AR Marra, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

Hepatitis B virus (HBV) is one of the most frequent pathogen worldwide and actively infects around 300 million people in the world. There is an effective recombinant vaccine available from almost 40 years. It is able to elicit protective antibodies levels in more than 95% of the vaccinated population. Nevertheless, HBV causes a chronic disease that in most cases may not be diagnosed for many years due to the absence of clear symptoms during the acute phase as well in the chronic phase before the establishment of severe clinical pictures as liver cirrhosis and hepatocellular carcinoma. To envisage the eradication of HBV, it will be necessary to warrant that (1) the vaccine against this virus was utilized in the whole population, preferentially adding it in national vaccine schedule as vaccination that should be started just after birth and to warrant (2) every infected patient access to effective treatment using pegylated α-interferon or nucleos(t)ide analogs. Hepatitis C virus (HCV) infects 100 to 200 million people around the world according to different statistics. There is not any effective vaccine to avoid this infection, but there are several new drugs called Direct Acting Anti-viral Agents (DAAs) that reach sustained response rate near 100% even with the presence of liver cirrhosis or HIV co-infection. This approach changed hepatitis C epidemiological picture from a widespread disease with large difficulties in succeeding in the treatment to a curable disease in most cases. Although these drugs will not lead to the eradication of hepatitis C, they will significantly decrease the burden of this disease, avoiding the evolution for severe clinical pictures, such as liver cirrhosis, liver failure, and hepatocellular carcinoma. The costs of these drugs shall significantly reduce to warrant these positive effects in the poor populations of underdeveloped countries, which comprehend an important portion of the infected population nowadays. Nevertheless, limited access to DAA treatment, delayed HCV detection, and reinfection after a successful treatment reinforces the need to develop a vaccine for global control of infection.

Hepatitis delta virus (HDV) is a subviral agent infecting only those who have already been infected with HBV (superinfection) or those who are co-infected with both agents. HDV is present in many different world regions, in some of them in higher frequency, such as in Northern South America, sub-Saharan and Mediterranean Africa, Middle East, and many countries in Central Asia. The presence of this virus is increasing around the world due to the recent immigrations. The measures to control HBV also avoid the spread of this infection, but it is necessary to establish more effective ways to treat those individuals already infected by this agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. National Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Washington, DC: The National Academies Press; 2016. doi:10.17226/23407.

    Google Scholar 

  2. Joint Society Statement for Elimination of Viral Hepatitis. http://ilc-congress.eu/wp-content/uploads/2016/04/Joint-Society-Statement-for-Elimination-of-Viral-Hepatitis.pdf. [Online] July 16, 2016.

  3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi:10.1016/S0140-6736(14)61682-2.

    Article  Google Scholar 

  4. •• Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016; doi:10.1016/S0140-6736(16)30579-7. An interesting analysis of the global burden of viral hepatitis in the world, including all its possible complications.

    Google Scholar 

  5. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. Geneva: WHO Document Production Services; 2016.

    Google Scholar 

  6. Curry MP, Chopra S. Acute viral hepatitis. In: Bennett JE, Dolin R Mandell GL. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Seventh ed. Philadelphia, PA: Elsevier, 2010, pp. 1577–1592.

  7. Debing Y, Moradpour D, Neyts J, Gouttenoire J. Update on hepatitis E virology: implications for clinical practice. J Hepatol. 2016;1:200–12. doi:10.1016/j.jhep.2016.02.045.

    Article  Google Scholar 

  8. Alvarado-Mora MV, Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. Antivir Ther. 2013;18(3 Pt B):429–33. doi:10.3851/IMP2595.

    PubMed  Google Scholar 

  9. Taylor DR. Evolution of cell culture systems for HCV. Antivir Ther. 2013;18(3 Pt B):523–30. doi:10.3851/IMP2593.

    Article  PubMed  Google Scholar 

  10. •• Alvarado-Mora MV, Locarnini S, Rizzetto M, Pinho JR. An update on HDV: virology, pathogenesis and treatment. Antivir Ther. 2013;18(3 Pt B):541–8. doi:10.3851/IMP2598. A recent review on hepatitis delta and its etiological agent.

    Article  PubMed  Google Scholar 

  11. Ozaras R, Tahan V. Acute hepatitis C: prevention and treatment. Expert Rev Anti-Infect Ther. 2009;7(3):351–61. doi:10.1586/eri.09.8.

    Article  CAS  PubMed  Google Scholar 

  12. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603.

    Article  CAS  PubMed  Google Scholar 

  13. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992–1000.

    Article  CAS  PubMed  Google Scholar 

  14. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099–108. doi:10.1002/hep.27406. Epub 2014 Oct.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Fitz JG. Hepatology after hepatitis C. Dig Dis. 2016;34(5):603–6. doi:10.1159/000445276.

    Article  PubMed  Google Scholar 

  16. •• Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi:10.1007/s12072-015-9675. This guideline provides the most up-to-date official recommendations for management of hepatitis B.

    Article  CAS  PubMed  Google Scholar 

  17. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int. 2014;34(Suppl 1):112–9. doi:10.1111/liv.12400.

    Article  CAS  PubMed  Google Scholar 

  18. Vlachogiannakos J, Papatheodoridis GV. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? Liver Int. 2014;34(Suppl 1):127–32. doi:10.1111/liv.12404.

    Article  CAS  PubMed  Google Scholar 

  19. Tuaillon E, Mondain AM, Nagot N, Ottomani L, Kania D, Nogue E, Rubbo PA, et al. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS One. 2012;7(3):e32143. doi:10.1371/journal.pone.0032143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. • Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36(Suppl 1):85–92. doi:10.1111/liv.13003. All the proposed new therapeutical approaches for hepatitis B are reviewed.

  21. Martel-Laferrière V, Dieterich DT. Hepatitis C direct-acting antiviral agents in HIV/HCV co-infected patients. Curr Treat Opt Infect Dis. 2014;6:132–43. doi:10.1007/s40506-014-0010-8.

    Article  Google Scholar 

  22. •• Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, et al. APASL consensus statements and recommendation on treatment of hepatitis. C Hepatol Int. 2016;10(5):702–26. doi:10.1007/s12072-016-9717-6. This guideline provides the most up-to-date official recommendations for management of hepatitis C.

    Article  PubMed  Google Scholar 

  23. Rizzetto M, Smedile A. Pegylated interferon therapy of chronic hepatitis D: in need of revision. Hepatology. 2015;61(4):1109–11. doi:10.1002/hep.27585.

    Article  CAS  PubMed  Google Scholar 

  24. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang. 2011;100(1):92–8. doi:10.1111/j.1423-0410.2010.01426.x.

    Article  CAS  PubMed  Google Scholar 

  25. Polizzotto MN, Wood EM, Ingham H, Keller AJ, Australian Red Cross Blood Service Donor and Product Safety Team. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. Transfusion. 2008;48(1):55–63.

    PubMed  Google Scholar 

  26. Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion. 2007;47(3):529–39.

    Article  PubMed  Google Scholar 

  27. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang. 2012;102(1):82–90. doi:10.1111/j.1423-0410.2011.01506.x.

    Article  CAS  PubMed  Google Scholar 

  28. Yarbrough ML, Burnham CA. The ABCs of STIs: an update on sexually transmitted infections. Clin Chem. 2016;62(6):811–23. doi:10.1373/clinchem.2015.240234.

    Article  CAS  PubMed  Google Scholar 

  29. Braga WS. Hepatitis B and D virus infection within Amerindians ethnic groups in the Brazilian Amazon: epidemiological aspects. Rev Soc Bras Med Trop. 2004;37(Suppl 2):9–13.

    Article  PubMed  Google Scholar 

  30. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis—United States, 2006. MMWR Surveill Summ. 2008;57:1–24.

    PubMed  Google Scholar 

  31. Chan DP, Sun HY, Wong HT, Lee SS, Hung CC. Sexually acquired hepatitis C virus infection: a review. Int J Infect Dis. 2016;49:47–58. doi:10.1016/j.ijid.2016.05.030.

    Article  PubMed  Google Scholar 

  32. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881–9. doi:10.1002/hep.26164.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, Krznaric I, Radun D. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany—a case-control study. PLoS One. 2011;6(3):e17781. doi:10.1371/journal.pone.0017781.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 2015;64(RR-03):1–13.

    PubMed  Google Scholar 

  35. • Thio CL, Guo N, Xie C, Nelson KE, Ehrhardt S. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis. 2015;15(8):981–5. doi:10.1016/S1473-3099(15)00158-9. The different approaches to deal with vertical transmission of hepatitis B are explained.

    Article  PubMed  Google Scholar 

  36. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol. 2012;4:74–80. doi:10.4254/wjh.v4.i3.74.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Revill P, Yuen L, Walsh R, Perrault M, Locarnini S, Kramvis A. Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses. J Med Virol. 2010;82(1):104–15. doi:10.1002/jmv.21645.

    Article  CAS  PubMed  Google Scholar 

  38. Pourkarim MR, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol. 2014;20(23):7152–68. doi:10.3748/wjg.v20.i23.7152.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kramvis A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev Med Virol. 2016;26(4):285–303. doi:10.1002/rmv.1885.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ramia S, Bahakim H. Perinatal transmission of hepatitis B virus-associated hepatitis D virus. Ann Inst Pasteur Virol. 1988;139(3):285–90.

    Article  CAS  PubMed  Google Scholar 

  41. François-Souquière S, Makuwa M, Bisvigou U, Kazanji M. Epidemiological and molecular features of hepatitis B and hepatitis delta virus transmission in a remote rural community in central Africa. Infect Genet Evol. 2016;39:12–21. doi:10.1016/j.meegid.2015.12.021.

    Article  PubMed  Google Scholar 

  42. Tovo PA, Calitri C, Scolfaro C, Gabiano C, Garazzino S. Vertically acquired hepatitis C virus infection: correlates of transmission and disease progression. World J Gastroenterol. 2016;22(4):1382–92. doi:10.3748/wjg.v22.i4.1382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. • Aebi-Popp K, Duppenthaler A, Rauch A, De Gottardi A, Kahlert C. Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland. J Virus Erad. 2016;2(1):52–4. Different approaches to control the vertical transmission of hepatitis C are discussed, including a possible use for DAAs.

    PubMed  PubMed Central  Google Scholar 

  44. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore). 2001;80(2):134–51.

    Article  CAS  Google Scholar 

  45. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis. 2012;54(8):1167–78. doi:10.1093/cid/cir991.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Deisenhammer S, Radon K, Nowak D, Reichert J. Needlestick injuries during medical training. J Hosp Infect. 2006;63:263–7. doi:10.1016/j.jhin.2006.01.019.

    Article  CAS  PubMed  Google Scholar 

  47. • Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016; doi:10.1016/j.cmi.2016.07.035. A review of the strategies to control hepatitis C.

    PubMed  Google Scholar 

  48. Sutton AJ, Hope VD, Mathei C, Mravcik V, Sebakova H, Vallejo F, et al. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. J Viral Hepat. 2008;15(11):809–16. doi:10.1111/j.1365-2893.2008.01041.x.

    CAS  PubMed  Google Scholar 

  49. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL, Strauss S. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend. 2007;89(1):1–12. doi:10.1016/j.drugalcdep.2006.11.014.

    Article  PubMed  Google Scholar 

  50. Mitsui T, Iwano K, Masuko K, Yamazaki C, Okamoto H, Tsuda F, Tanaka T, Mishiro S. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology. 1992;16(5):1109–14. doi:10.1002/hep.1840160502.

    Article  CAS  PubMed  Google Scholar 

  51. Fabrizi F, Dixit V, Messa P, Martin P. Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38(1):1–7. doi:10.5301/ijao.5000376.

    Article  PubMed  Google Scholar 

  52. • Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines. 2014;13(11):1317–26. doi:10.1586/14760584.2014.944508. A review on hepatitis B in chronic kidney disease patients and its control.

    Article  CAS  PubMed  Google Scholar 

  53. Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38(9):471–80. doi:10.5301/ijao.5000437.

    Article  PubMed  Google Scholar 

  54. • Fabrizi F, Messa P. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population? Expert Rev Clin Pharmacol. 2015;8(6):785–93. doi:10.1586/17512433.2015.1086266. A review on hepatitis C in chronic kidney disease patients and its control.

    Article  CAS  PubMed  Google Scholar 

  55. Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015;29(6):907–17. doi:10.1016/j.bpg.2015.09.011.

    Article  PubMed  Google Scholar 

  56. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–25. doi:10.1093/epirev/mxj009.

    Article  PubMed  Google Scholar 

  57. Divisão de Imunização. Divisão de Hepatites. Centro de Vigilância Epidemiológica “Prof. Alexandre Vranjac”. Coordenadoria de Controle de Doenças. Secretaria de Estado da Saúde de São Paulo – DI/DH/CVE/CCD/SESSP. Vacina contra hepatite B. [Hepatitis B vaccine]. Rev Saude Publica. 2006;40(6):1137–40.(article in Portuguese) doi:10.1590/S0034-89102006000700026.

  58. Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392–403.

    Article  CAS  PubMed  Google Scholar 

  59. Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21:3623–8. doi:10.1016/S0264-410X(03)00399-2.

    Article  CAS  PubMed  Google Scholar 

  60. Orenstein WA, Pickering, L.K., Mawle, A., Hinman, A.R., Wharton, M. Immunization. In: J.E. Mandell GL Bennett. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Elsevier, 2010, pp. 1577–92.

  61. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23(30):3876–86. doi:10.1016/j.vaccine.2005.03.005.

    Article  CAS  PubMed  Google Scholar 

  62. Zanetti AR, Mariano A, Romanò L, D’amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366(9494):1379–84. doi:10.1016/S0140-6736(05)67568-X.

    Article  CAS  PubMed  Google Scholar 

  63. van der Sande MAB, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One. 2007;2(8):e753. doi:10.1371/ journal.pone.0000753.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Su FH, Chu FY, Bai CH, Lin YS, Hsueh YM, Sung FC, Yeh CC. Efficacy of hepatitis B vaccine boosters among neonatally vaccinated university freshmen in Taiwan. J Hepatol. 2013;58(4):684–9. doi:10.1016/j.jhep.2012.11.036.

    Article  CAS  PubMed  Google Scholar 

  65. Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. Expert Rev Anti-Infect Ther. 2004;2(1):133–45.

    Article  CAS  PubMed  Google Scholar 

  66. •• Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines. 2016;13:1–10. doi:10.1080/14760584.2016.1194759. New formulations for hepatitis C vaccines.

    Google Scholar 

  67. Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, et al. The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals? PLoS One. 2016;11(5):e0156213. doi:10.1371/journal.pone.0156213.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Freeman ZT, Cox AL. Lessons from nature: understanding immunity to HCV to guide vaccine design. PLoS Pathog. 2016;12(6):e1005632. doi:10.1371/journal.ppat.1005632.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

João Renato Rebello Pinho receives a fellowship from CNPq (Bolsa de Produtividade em Pesquisa do CNPq—Nível 2). Fernanda de Mello Malta receives grant from CNPq (Universal - 443152/2014-4).

Author information

Authors and Affiliations

  1. LIM-O7, Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de São Paulo, Avenida Doutor Enéas de Carvalho Aguiar 470, Jardim América, São Paulo, SP, 05403-000, Brazil

    João Renato Rebello Pinho M.D., Ph.D., MBA, Fernanda de Mello Malta Ph.D & Michele Soares Gomes-Gouvêa Ph.D

  2. Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

    João Renato Rebello Pinho M.D., Ph.D., MBA

Authors
  1. João Renato Rebello Pinho M.D., Ph.D., MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernanda de Mello Malta Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Soares Gomes-Gouvêa Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to João Renato Rebello Pinho M.D., Ph.D., MBA.

Ethics declarations

Conflict of interest

João Renato Rebello Pinho declares that he has no conflict of interest. Fernanda de Mello Malta declares that she has no conflict of interest. Michele Soares Gomes-Gouvêa declare that she has no conflict of interest.

Human and animal rights and informed consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. In addition, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Additional information

This article is part of the Topical Collection on New Technologies and Advances in Infection Prevention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pinho, J.R.R., de Mello Malta, F. & Gomes-Gouvêa, M.S. Hepatitis B, C, and Delta—Updates in Screening and Infection Prevention Opportunities for Eradication. Curr Treat Options Infect Dis 9, 18–33 (2017). https://doi.org/10.1007/s40506-017-0105-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-017-0105-0

Keywords

Search

Navigation